Prana candidate reduces Abeta levels
Thursday, 10 July, 2008
Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.
The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.
PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.
The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
